Now, that account is worth $55,000, with a 65% concentration in Nvidia (NVDA), which was my first stock buy, then a 20% concentration in Novo Nordisk (NVO) and Eli Lilly (LLY) stock, with 15% ...

Deadline's Doc Talk podcast dissects what Ezra Edelman said about Netflix's decision to abandon his Prince documentary series.

Lincoln Center Theater celebrated the opening night of Ibsen’s Ghosts, featuring a new version by Mark O’Rowe and direction ...

The Vanguard Mega Cap ETF is outperforming the S&P 500 but lagging peers like XLG and OEF. Read more on the analysis of MGC ...

A former NFL linebacker was sentenced in Los Angeles on Monday for running a Ponzi Scheme that defrauded his victims of $5.3 ...

As earnings season begins, filings to the SEC point to uncertainty from the current administration as potential trouble for ...

Director Robert Eggers’ macabre masterpiece creeps from silver screens to home theaters in the 4K disc format in “Nosferatu.” ...

Singer Lily Allen and David Harbour have reportedly called it quits on their four-year marriage after months of speculation that their relationship was on the rocks. Allen, 39, and Harbour ...

Back in December, I argued why I was ready to upgrade the stock of the embattled weight loss drugs leader Eli Lilly and Company (NYSE:LLY) even as it fell into a bear market after peaking in August.

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. The company launched 7.5 mg and 10 mg vials of ...

Eli Lilly LLY-2.01%decrease; red down pointing triangle is expanding its offerings of its hit weight-loss drug Zepbound for people who want to pay cash instead of using their health plans ...

Eli Lilly is buying a new drug and lowering prices on an existing one. GLP-1 weight loss drug Zepbound is getting cheaper. This will make Lilly's product relatively more attractive, and help to ...